With sales of Immunocore’s melanoma medicine steadily ticking up, an expanded label likely down the line and a longtime colleague no longer at her side, CEO Bahija Jallal, Ph.D., is mixing caution with ambition as she adjusts to working without a longtime colleague at her side.
- Home |
- After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
- February 13, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
